20 results
8-K
EX-99.1
PRLD
Prelude Therapeutics Inc
15 Feb 24
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
4:22pm
to enroll eligible patients, supply chain and manufacturing facilities, Prelude’s ability to maintain and recognize the benefits of certain designations
8-K
EX-99.1
PRLD
Prelude Therapeutics Inc
11 Dec 23
Prelude Therapeutics Announces $25 Million Private Placement
9:17am
, approvals and commercialization of product candidates, clinical trial sites and our ability to enroll eligible patients, supply chain and manufacturing
8-K
EX-99.1
PRLD
Prelude Therapeutics Inc
1 Nov 23
Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
4:23pm
and commercialization of product candidates, clinical trial sites and our ability to enroll eligible patients, supply chain and manufacturing facilities, Prelude’s
8-K
EX-99.1
PRLD
Prelude Therapeutics Inc
3 Aug 23
Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
8:10am
and commercialization of product candidates, clinical trial sites and our ability to enroll eligible patients, supply chain and manufacturing facilities, Prelude’s
8-K
EX-99.2
7yq pxag1styiq4us7k
19 May 23
Prelude Therapeutics Announces Launch of Proposed Public Offering
4:06pm
8-K
EX-99.1
4hd4z5 mrreogf8lt
19 May 23
Prelude Therapeutics Announces Launch of Proposed Public Offering
4:06pm
8-K
EX-99.1
0ittm335aur 0d8of
8 May 23
Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update
8:06am
8-K
EX-99.1
uq3b4i skyvm7cxnlm
14 Nov 22
Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update
8:21am
8-K
EX-99.1
0kt hq5d7bjyee5
9 Aug 22
Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
8:02am
8-K
EX-99.1
lrvk3k
10 May 22
Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update
8:05am
8-K
EX-99.1
epxufviiqrt28yzi3a
16 Mar 22
Prelude Therapeutics Reports Full Year 2021 Financial Results
8:05am
8-K
EX-99.2
b20rv9t qx
9 Mar 22
Jane Huang, M.D., Joins Prelude Therapeutics as President and Chief Medical Officer
8:22am
8-K
EX-99.1
3agy9cn0d
9 Mar 22
Jane Huang, M.D., Joins Prelude Therapeutics as President and Chief Medical Officer
8:22am
8-K
EX-99.1
sv699iftkeut 3m5g
12 Nov 21
Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update
7:57am
8-K
EX-99.1
mwumn1s
12 Aug 21
Prelude Therapeutics Announces Second Quarter 2021 Financial Results and Operations Update
10:41am
8-K
EX-99.1
28rtvp a4d
11 May 21
Prelude Therapeutics Announces First Quarter 2021 Financial Results and Operations Update
8:00am
8-K
EX-99.1
8iu1mm u1t
16 Mar 21
Prelude Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Update
8:10am
8-K
EX-99.1
aw8i6by0rrti31c7x
10 Nov 20
Prelude Therapeutics Announces Third Quarter 2020 Financial Results
7:37am
- Prev
- 1
- Next